KPV 500mcg x 100 capsules

Description

What is KPV?

KPV (H‑Lys‑Pro‑Val‑OH) is the C‑terminal tripeptide of α‑MSH. Unlike the full α‑MSH molecule, KPV exhibits anti‑inflammatory effects largely independent of melanocortin receptors, and has been studied in rodent models of inflammatory bowel disease, atopic dermatitis, and skin wounds.

Mechanism of Action

• Intracellular inhibition of NF‑κB signaling and downstream pro‑inflammatory cytokine transcription (TNF‑α, IL‑1β, IL‑6)
• Reduces neutrophil and mast‑cell infiltration in inflamed tissue
• Proposed antimicrobial activity against C. albicans and S. aureus in in‑vitro studies
• Does not bind melanocortin receptors appreciably; anti‑inflammatory effect is MC‑receptor‑independent

Compound Properties

• Molecular formula: C₁₆H₃₀N₄O₄
• Molecular weight: ~342.44 g/mol
• Sequence: Lys‑Pro‑Val (H‑K‑P‑V‑OH)
• Form: Oral capsule
• Unit size: 500 µg per capsule × 100 capsules
• Source: Solid‑phase peptide synthesis; ≥98% purity by HPLC

Research‑Reference Dosing

Published research‑reference ranges in preclinical literature:

• Kannengiesser et al., Inflammatory Bowel Diseases (2008): oral KPV reduced colitis severity in DSS and TNBS rodent models.
• Dalmasso et al., Gastroenterology (2008): PepT1‑mediated enterocyte uptake delivered KPV directly to gut epithelium, reducing inflammation at low µg doses.
• Human efficacy data is limited; most published data is preclinical.

Research Findings

• Attenuated DSS and TNBS colitis in rodents with oral or rectal dosing (Kannengiesser 2008)
• Reduced dermal inflammation in atopic‑dermatitis mouse models
• Investigated as an oral delivery candidate (PepT1 transporter recognition)

Known Side Effects Reported in Research/Trials

• Generally well tolerated in preclinical studies
• Injection‑site reactions when administered parenterally
• No characteristic human safety profile established

Storage & Handling

• Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
• After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
• Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.

Certificate of Analysis

A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.

Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.